DCGI warns against overpricing, shortage

NEWDELHI:AFTER receiving several complaints of drug shortages, India’s drugs controller on Tuesday directed state authorities to ensure there is no black marketing or over-pricing of the antiviral drug remdesivir that it has allowed under emergency use authorization for severely ill patients of Covid-19.the drugs controller acted on a complaint by Local Circles, an independent community engagement and social media platform, which pointed to the problem of drug shortage because of alleged black-marketing.

In a letter to state drug controllers, Drugs Controller General of India VG Somani said: “… this office has received a letter from M/s Local Circles, through ministry of health, raising concerns regarding black marketing and over pricing of the drug Remdesivir by certain unscrupulous persons.” He added: “In view of the above, you are requested to instruct your enforcement officials to keep strict vigil on the matter to prevent black-marketing and sale of the drug Remdesivir injection above maximum retail price.”over the past few days, people and hospitals have been finding it hard to procure the drug. “Our hospital is wellstocked but the drug is in short supply in market and many hospitals have approached us to buy some doses from us. It is not sold in our Out Patient Department pharmacy but is given directly to admitted patients,” said a person in a private hospital in Delhi, who did not wish to be named.

On Monday, Sachin Taparia, chairman and CEO, Local Circles, wrote to the authorities, saying, “… over the last 72 hours, many posts and comments were received from citizens across India… about the black marketing of the drug Remdesivir.”

The complaint said a vial that costs about ~5,500 was being sold for anywhere between ₹15,000 and 60,000. The drugs controller has granted permission for manufacturing and sale of the drug to three Indian companies-- Cipla Limited, Hetero Drugs Limited, and Mylan Laboratories Limited